“
“Biliary tract carcinomas (BTCs) are difficult to diagnose and treat. Epidermal growth factor receptor (EGFR) represents a therapeutic target for the BTCs.

Mutations of the EGFR gene and the activation of its downstream pathways, including KRAS and BRAF, predict the sensitivity to anti-EGFR treatment. The aims of this selleck screening library study were to analyze the EGFR, KRAS and BRAF mutations in BTCs and their association with clinical outcomes. Paraffin-embedded specimens containing 137 BTCs resected at the National Taiwan University Hospital between 1995 and 2004 were analyzed. The exons 18–21 of EGFR gene, the codon 12, 13 and 61 of KRAS gene, and BRAF V600E mutation were analyzed. We examined the correlation between

these mutations and the overall survival, tumor location, stage, and differentiation in BTCs. Thirteen (9.5%) BTC patients had EGFR mutations while 23 (16.8%) patients had KRAS mutations. Only one patient had BRAF mutation. Factors influencing survival on univariate analysis were tumor stage, tumor differentiation, and EGFR mutation. On multivariate analysis, EGFR mutation and tumor stage were independent prognostic factors. A correlation between KRAS or BRAF mutations and prognosis was not observed. EGFR and KRAS mutations are not uncommon in BTCs. BRAF mutation is rare in BTCs. EGFR mutation was an independent prognostic marker in BTCs in addition to tumor stage and differentiation. No

simultaneous Venetoclax datasheet EGFR and KRAS mutations in extrahepatic cholangiocarcinoma and gallbladder carcinoma were found. EGFR and KRAS mutations should be evaluated when tailoring molecular-targeted therapy to patients with BTCs. “
“We read with great interest the article recently published in this journal.1 In that study, Sookoian and Pirola presented the results of a meta-analysis including 2,651 patients undergoing liver biopsy, in which the strength of I148M patatin-like phospholipase domain-containing protein 3 (PNPLA3) variant on nonalcoholic fatty liver disease (NAFLD) severity across different populations was evaluated, together with its potential influence on intermediate associated phenotypes. The power of this study has shown that the I148M polymorphism impacts not only hepatic triglyceride content, but also DNA ligase the susceptibility toward a more aggressive disease (i.e., liver fibrosis). The I148M variant also influences alanine aminotransferase activity, without affecting body mass, insulin resistance, or serum lipid levels. The large dataset investigated allowed measurement of the strength of PNPLA3 genotypes on NAFLD and disease severity, which was consistent with an additive genetic model, with the only exception of a likely dominant effect of the G allele onto fibrosis. Notably, the GG genotype was associated with a 73% increase in hepatic fat content and a 3.